Abstract
Inhibition of prostanoid synthesis is usually regarded as the mode of action of nonsteroidal antiinflammatory drugs (NSAIDs). In addition, some NSAIDs have been reported to have prostanoid-independent inhibitory effects on neutrophil functions. In the present study, we examined the effects of acetylsalicylic acid, diclofenac, indomethacin, ketoprofen, piroxicam and tolfenamic acid on leukotriene B4 (LTB4)-induced chemotaxis of human polymorphonuclear leukocytes (PMNs) in vitro. Tolfenamic acid inhibited LTB4-induced chemotaxis (IC50 59μM), whereas the other compounds were ineffective. Tolfenamic acid inhibited also FMLP-induced chemotaxis at the same concentration range (IC50 46μM). About 25% reduction in the chemotactic response was achieved with therapeutic concentrations of tolfenamic acid. We suggest that the inhibition of PMN chemotaxis is an additional mechanism in the antiinflammatory action of tolfenamic acid and that this action is not ligand specific.
Similar content being viewed by others
References
Goetzl, E.J., andW.C. Pickett. 1980. The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs).J. Immunol. 125:1789–1791.
Ford-Hutchinson, A.W., M.A. Bray, M.V. Doig, M.E. Shipley, andM.J.H. Smith. 1980. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorpho-nuclear leukocytes.Nature 286:264–265.
Palmblad, J., C.L. Malmsten, A.M. Uden, O. Rådmark, L. Engstedt, andB. Samuelsson. 1981. Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence.Blood 58:658–661.
Soter, N.A., R.A. Lewis, E.J. Corey, andK.F. Austen. 1983. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4 and LTB4) in human skin.J. Invest. Dermatol. 80:115–119.
Camp, R.D.R., A.A. Coutts, M.W. Greaves, A.B. Kay, andM.J. Walport. 1983. Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4.Br. J. Pharmacol. 80:497–502.
Brain, S.D., R.D. Camp, M.W. Greaves, R. Russeljones, andP.M. Woollard. 1984. The inflammatory responses of human skin to topical application of leukotriene B4.Br. J. Clin. Pharmacol. 17:610P-611P.
Klickstein, L.B., C. Shapleigh, andE.J. Goetzl. 1980. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis.J. Clin. Invest. 66:1166–1170.
Davidson, E.M., S.A. Rae, andM.J.H. Smith. 1983. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis.Ann. Rheum. Dis. 42:677–679.
Rae, S.A., E.M. Davidson, andM.J.H. Smith. 1982. Leukotriene B4, an inflammatory mediator in gout.Lancet 2:1122–1123.
Brain, S.D., R.D.R. Camp, P.M. Dowd, A.K. Black, P.M. Woollard, A.I. Mallet, andM.W. Greaves. 1982. Psoriasis and leukotriene B4.Lancet 2:762–763.
Grabbe, J., B.M. Czarnetzki, andM. Mardin. 1982. Chemotactic leukotrienes in psoriasis.Lancet 2:1464.
Abramson, S.B., andG. Weissmann. 1989. The mechanisms of action of nonsteroidal antiinflammatory drugs.Arthritis Rheum. 32:1–9.
Kaplan, H.B., H.S. Edelson, H.M. Korchak, W.P. Given, S. Abramson, andG. Weissmann. 1984. Effects of non-steroidal anti-inflammatory agents on human neutrophil functions in vitro and in vivo.Biochem. Pharmacol. 33:371–378.
Smith, M.J.H., andJ.R. Walker. 1980. The effects of some antirheumatic drugs on an in vitro model of human polymorphonuclear chemokinesis.Br. J. Pharmacol. 69:473–478.
Perianin, A., M.-A. Gougerot-Pocidalo, J.-P. Giroud, andJ. Hakim. 1985. Diclofenac sodium, a negative chemokinetic factor for neutrophil locomotion.Biochem. Pharmacol. 34:3433–3438.
Tanaka, K., K. Kanaoka, M. Egawa, N. Abe, I. Watanabe, andS. Hirai. 1984. Inhibition of in vitro neutrophil responses to chemotactic factors by piroxicam.Jpn. J. Pharmacol. 35:181–191.
Kemp, A.S., andJ. Smith. 1982. The effect of salicylate on human leucocyte migration.Clin. Exp. Immunol. 49:233–238.
`Bøyum, A. 1976. Isolation of lymphocytes, granulocytes and macrophages.Scand. J. Immunol. 5(suppl):9–15.
Gallin, J.I., R.A. Clark, andH.R. Kimball. 1973. Granulocyte chemotaxis: an improved in vitro assay employing51 Cr-labeled granulocytes.J. Immunol. 110:233–240.
Mishell, B.B., andS.M. Shiigi. 1980. In vitro immune responses.In Selected Methods in Cellular Immunology. B.B. Mishell, and S.M. Shiigi, editors. W.H. Freeman and Company, San Francisco. 1–166.
Moilanen, E., J. Alanko, E. Seppälä, and H. Vapaatalo. 1988. Effects of antirheumatic drugs on leukotriene B4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro.Agents Actions 24:387–394.
Pentikäinen, P.J., P.J. Neuvonen, andC. Backman. 1981. Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent.Eur. J. Clin. Pharmacol. 19:359–365.
Williams, L.T., R. Snyderman, M.C. Pike, andR.J. Lefkowitz. 1977. Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes.Proc. Natl. Acad. Sci. U.S.A. 74:1204–1208.
Goldman, D.W., andE.J. Goetzl. 1982. Specific binding of leukotriene B4 to receptors on human polymorphonuclear leukocytes.J. Immunol. 129:1600–1604.
Moilanen, E., J. Alanko, A. Juhakoski, andH. Vapaatalo. 1989. Orally administered tolfenamic acid inhibits leukotriene synthesis in isolated human peripheral polymorphonuclear leukocytes.Agents Actions 26:83–88.
Perez, H.D., F. Elfman, andS. Marder. 1987. Meclofenamate sodium monohydrate inhibits chemotactic factor-induced human polymorphonuclear leukocyte function.Arthritis Rheum. 30:1023–1031.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kankaanranta, H., Moilanen, E. & Vapaatalo, H. Tolfenamic acid inhibits leukotriene B4-induced chemotaxis of polymorphonuclear leukocytes in vitro. Inflammation 15, 137–143 (1991). https://doi.org/10.1007/BF00917508
Issue Date:
DOI: https://doi.org/10.1007/BF00917508